EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis

April W Armstrong, Melinda Gooderham, Charles Lynde, Catherine Maari, Seth Forman, Lawrence Green, Vivian Laquer, Xinyan Zhang, Nathalie Franchimont, Esha A Gangolli, Jessamyn Blau, Yiwei Zhao und 4 weitere

JAMA Dermatology · 01.10.2024 · 160 (10) · 1066

DOI: 10.1001/jamadermatol.2024.2701 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.10.2024. Verfasst von April W Armstrong und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles. Hauptthemen laut MEDLINE: Psoriasis, Severity of Illness Index. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.

Objective

To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis. Design, Setting, and Participants This phase 2b, randomized, double-blind, placebo-controlled, multiple-dose randomized clinical trial was conducted from August 11, 2021, to September 12, 2022, at 47 centers in the US and 8 in Canada. The study included a 12-week treatment period and a 4-week follow-up period. Key eligibility criteria for participants included age 18 to 70 years; a Psoriasis Area and Severity Index (PASI) score of 12 or greater; a Physician’s Global Assessment score of 3 or greater; and a body surface area covered by plaque psoriasis of 10% or greater. Of 287 patients randomized, 259 (90.2%) received at least 1 dose of study treatment.

Intervention

Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks. Main Outcomes and Measures The primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed.

Results

In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters. Conclusions and Relevance This randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks. Trial Registration ClinicalTrials.gov Identifier: NCT04999839

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisSeverity of Illness IndexHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultTreatment OutcomeProtein Kinase InhibitorsAdministration, OralAgedDose-Response Relationship, DrugYoung AdultFollow-Up StudiesBenzimidazolesQuinolones

Substanzen

Protein Kinase Inhibitors4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneBenzimidazolesQuinolones

Autor:innen und Institutionen

  • University of California, Los Angeles.
  • SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada.
  • Lynde Institute for Dermatology and Probity Medical Research, Markham, Ontario, Canada.
  • Innovaderm Research, Montreal, Quebec, Canada.
  • ForCare Medical Center, Tampa, Florida.
  • George Washington University School of Medicine, Rockville, Maryland.

Zitieren

APA

Armstrong, A. W., Gooderham, M., Lynde, C., Maari, C., Forman, S., Green, L., Laquer, V., Zhang, X., Franchimont, N., Gangolli, E. A., Blau, J., Zhao, Y., Zhang, W., Srivastava, B., Heap, G., & Papp, K. (2024). Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis. JAMA Dermatology, 160(10), 1066. https://doi.org/10.1001/jamadermatol.2024.2701

Vancouver

Armstrong AW, Gooderham M, Lynde C, Maari C, Forman S, Green L, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis. JAMA Dermatology. 2024;160(10):1066. doi:10.1001/jamadermatol.2024.2701

BibTeX
@article{Armstrong2024,
  author = {Armstrong, April W and Gooderham, Melinda and Lynde, Charles and Maari, Catherine and Forman, Seth and Green, Lawrence and Laquer, Vivian and Zhang, Xinyan and Franchimont, Nathalie and Gangolli, Esha A and Blau, Jessamyn and Zhao, Yiwei and Zhang, Wenwen and Srivastava, Bhaskar and Heap, Graham and Papp, Kim},
  title = {Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis},
  journal = {JAMA Dermatology},
  year = {2024},
  volume = {160},
  number = {10},
  pages = {1066},
  doi = {10.1001/jamadermatol.2024.2701}
}
Kostenlos starten →